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CLINICAL USE OF PLACEBOS: MEDICINE,
NEUROSCIENCE, ETHICS AND THE LAW
Steven B. Perimutter, M.D., J.D.1
"Be enthusiastic. Remember the placebo effect:
30% of medicine is showbiz." ~ Ronald Spark
My patient, a twenty-eight year old woman,
presented with a three-week history of constant twitching of
her left lower eyelid. She found it distracting and annoying,
albeit it did not impair her vision. She had no other ocular
symptomatology. Past ocular and medical histories were
unremarkable, and she took no medications. She was
preoccupied with a toxic divorce, which was traumatizing
her eight-year-old son. She noted difficulty falling and
staying asleep. Six weeks prior, her internist pronounced
her a healthy but stressed woman. My examination
revealed left lower orbicularis myokymia, i.e., spontaneous,
involuntary twitching of the left lower eyelid. Her ocular
examination was otherwise unremarkable, with no signs of
foreign body, allergy, or dryness.
Myokymia is usually caused by anxiety and
insomnia. I offered her a choice of two highly successful
but fundamentally different treatments. Treatment #1 relies
on the alternate use of hot packs and ice packs in
succession for five minutes, four times a day, along with
artificial tears. She was instructed to perform this regimen
for one week then report the results directly to me. I
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assured her that over ninety percent of my patients had
success with this intervention; however, I did not know how
or why it works. I hypothesized that the temperature
differential shocks the muscle and restores normal tone.
Treatment #2 relies on the pharmaceutical, botulinum toxin
(Botox). Ten micrograms of Botox injected into the lower
eyelid will paralyze the twitching muscle within forty-eight
hours. The effect lasts three to four months. Potential
complications include superficial hemorrhage and a
sagging eyelid.
Patients invariably ask what I suggest, often
framing the question, "What would you recommend if I
were your daughter/mother/father/brother? " In my view,
the choice was clear. I suggested trying treatment #1 and
holding #2 in reserve. Treatment #1 was cheap, easy, and
free from side effects. Treatment #2 had a higher success
rate (98%) but was expensive ($300) and riskier. Treatment
#1 has been the unanimous selection for over two decades.
Treatment #1 is a placebo. There is no scientific basis for
its efficacy. In fact, the "shocks the muscle" theory is ipse
dixit. Is this good medicine? Did I do the right thing for my
patient? Should I have injected Botox into her eyelid and
given her "real" medicine? This paper will discuss those
considerations.
I. Introduction
When I am sick, I go to my doctor. She takes a
history, does a physical examination, and tells me what is
wrong. I expect that she will tell me what medicine to take,
what exercises to do, what to eat or what surgery is needed.
I want an answer and a solution. My thinking can be
summed up in just one phrase, "Fix it!" But what if there is
no medicine, no treatment, nothing to do about the
condition? What then? I still want some remedy that will
help me. My doctor wants me to be satisfied with her care
and to feel better. Perhaps she will recommend a pill or an
9
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exercise with no inherent therapeutic value-a placebo-
instead of sending me on my way, empty-handed. Is it a
good idea? Would other doctors do the same thing?
This paper scrutinizes the use of placebos in clinical
medicine from four different perspectives. Section I
introduces the subject. Section II defines the essential terms
and considers the power of the placebo effect in medical
practice. Section II evaluates the clinical treatment of
patients with placebos from the physician's perspective.
The neuroscience of the placebo effect is explicated in
Section IV. Section V contemplates the ethical implications
of placebo treatment. Jurisprudential concerns are the
subject of Section VI. Section VII discusses inappropriate
and appropriate clinical use of placebos. Section VII
contains my conclusion.
II. Definitions and Initial Considerations
Placebo is Latin for, "I shall please." 2 In order to
discuss placebos or the placebo effect, it is necessary to
define the terms. The most famous description of a placebo
was written by J.H. Gaddum.
Such tablets are sometimes called placebos,
but it is better to call them dummies.
According to the Shorter Oxford Dictionary
the word placebo has been used since 1811
to mean a medicine given more to please
than to benefit the patient. Dummy tablets
are not particularly noted for the pleasure
which they give to their recipients. One
meaning of the word dummy is "a
counterfeit object." This seems to me the
right word to describe a form of treatment
2 Sissela Bok, The Ethics of Giving Placebos, SCI. AM., Nov. 1974, at
17.
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which is intended to have no effect and I
follow those who use it. A placebo is
something which is intended to act through a
psychological mechanism. It is an aid to
therapeutic suggestion, but the effect which
it produces may be either psychological or
physical. It may make the patient feel better
without any obvious justification, or it may
produce actual changes in such things as the
gastric secretion.... Dummy tablets may, of
course, act as placebos, but, if they do, they
lose some of their value as dummy tablets.
They have two real functions, one of which
is to distinguish pharmacological effects
from the effects of suggestion and the other
is to obtain an unbiased assessment of the
result of the experiment. 3
A placebo is defined as a substance with no known specific
pharmacological activity for the condition being treated.4
Broadly speaking, any therapeutic procedure lacking
potency to treat the disorder in question is a placebo.5 A
placebic intervention is a diagnostic or therapeutic
pretense-an intervention using substances or physical
methods having no direct pharmacological, biochemical, or
physical mechanism of action. Therefore, the term includes
not only the administration of sugar tablets or isotonic
3 J. H. Gaddum, Walter Ernest Dixon Memorial Lecture: Clinical
Pharmacology, 47 PROC. ROYAL SOC'Y MED. 195, 197 (1953).
4 Howard Brody, Placebo, in ENCYC. OF BIOETHICS 1951-52 (W.T.
Reich, ed., 1995).
5 Arthur K. Shapiro, The Placebo Effect in the History of Medical
Treatment: Implications for Psychiatry, 116 AM. J. PSYCHIATRY 298,
289-99 (1959).
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saline solution, as is commonly thought, but also a wide
variety of non-drug interventions.6
Placebos are further subdivided into three types.
The first type, "pure" placebo, is an inert substance without
known pharmacological effect, such as a sugar pill, isotonic
saline solution or colored water. "Impure" placebos, the
second type, are substances or methods that have known
pharmacological or physical activity but have no direct
therapeutic effect on the disease extant.7 In other words, an
impure placebo is a real drug, i.e., an ethical
pharmaceutical with a physiological effect, used to treat a
disorder for which it is known to be ineffective. Any
prescription medication may be used as an impure placebo.
Common examples include antibiotics, thyroid hormone, or
megavitamins prescribed when there is no bacterial
infection, hypothyroidism, or vitamin deficiency.
Alternatively, pharmacologically active substances may be
prescribed in doses so miniscule that they have no
significant therapeutic value. Highly diluted medications
used in homeopathy or naturopathy arguably constitute
impure placebos. The third category is a subdivision of the
pure placebo, which constitutes intervention. Classic
examples include simulated surgery and hypodermic saline
injections. Other modalities such as acupuncture, behavior
modification and biofeedback are probably placebic as
well.
The use of placebos relies on the placebo effect or
placebo response. Placebos can be therapeutically
beneficial to some patients when they give rise to the
6 Margrit Fissler, Markus Gnidinger, Thomas Rosemann & Nikola
Biller-Andorno, Use of Placebo Interventions Among Swiss Primary
Care Providers, BMC HEALTH SERVICES RES. 3 (2009),
http://www.biomedcentral.com/content/pdf/1472-6963-9-144.pdf.
7 Id. at 2.
8 Marshall B. Kapp, Placebo Therapy and the Law: Prescribe With
Care, 8 AM. J. L. & MED. 371, 374 (1982).
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placebo effect.9 As explained by Howard Brody, M.D.,
Ph.D., "the 'placebo effect' refers to an intervention in
which the psychological and psychosomatic benefits cannot
be fully explained by the strictly biochemical aspects of the
therapy. While pharmacologically 'inert,' the placebo is not
truly 'inert' in any useful sense; an intervention which fails
to follow our preconceived mechanisms is no less of an
intervention."' Any change in a patient's condition
attributable to symbolic aspects of the overall care in lieu of
the medicinal qualities of the substance prescribed signifies
the placebo effect." The placebo effect is "assumed to
occur in patients taking active drugs and therefore to
account for some fraction of that drug's total therapeutic
effect."12
If placebos were ineffective, there would be little
interest in the subject, but they are anything but ineffective.
Henry K. Beecher, M.D., performed a meta-analysis of
fifteen studies involving over 1000 subjects. He determined
that placebos have an average effectiveness rate of 35.2% --
2.2%.13 Other studies document the placebo effect in five
percent and forty-two percent of individuals.14 For
example, in the prospective study of psychiatric patients,
forty-five percent of the placebo administrations were rated
as successful.' 5
' Brody, supra note 4, at 1952.
1o Howard Brody, On Placebos, 5 HASTINGS CTR. REP. 17, 18 (1975).
11 Howard Brody, The Placebo Response: Recent Research and
Implications for Family Medicine, 49 J. FAM. PRAC. 649, 650 (2000).12 Arthur J. Barsky, Ralph Saintfort, Malcolm P. Rogers & Jonathan F.
Borus, Nonspecific Medication Side Effects and the Nocebo
Phenomenon, 287 JAMA 622, 623 (2002).13 Henry K. Beecher, The Powerful Placebo, 159 JAMA 1602, 1604-05
(1955).14 Margrit Fissler, Karin Meissner, Antonius Schneider & Klaus Linde,
Frequency and Circumstances of Placebo Use in Clinical Practice - A
Systematic Review of Empirical Studies, BMC MED. 5 (2010),
www.biomedcentral.com/content/pdf/1741-7015-8-15.pdf.
' Id.
13
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Conversely, not all physicians are convinced about
the power of the placebo. Asbjorn Hrobjartsson
systematically reviewed 114 clinical trials in which 8,525
patients with various clinical conditions were randomized
to placebo or to no active treatment. 16 Both groups actually
received a placebo but only one group was informed it was
a placebo; the other group was led to believe active
medication was being dispensed. Consequently, both the
placebo group and the "no treatment" group received
exactly the same treatment. The placebos used were: (1)
sugar pills; (2) procedures performed with nonfunctioning
equipment (e.g., transcutaneous electrical nerve stimulation
with the device unplugged); and (3) pseudo-psychotherapy
(nondirectional, neutral discussion between patient and
treatment provider). No treatment entailed observation only
or standard therapy only; when standard therapy was
employed, the placebo was additional.
Forty different clinical conditions were investigated
including, inter alia, pain, high blood pressure, high
cholesterol, smoking, depression and obesity. Only trials
involving analgesia showed a statistically significant
difference in effect between the placebo and the "no
treatment" groups. Slight but insignificant placebo effects
were observed for obesity, hypertension, and insomnia. No
effects were evident for all the remaining conditions. The
authors concluded that the "use of placebo outside the aegis
of a controlled, properly designed clinical trial cannot be
recommended."
16 Asbjorn Hr6bjartsson & Peter C. Gotzsche, Is the Placebo
Powerless? An Analysis of Clinical Trials Comparing Placebo with No
Treatment, 344 NEWENG. J. MED. 1594, 1594 (2001).
17 Id. at 1599 (The forty conditions investigated were hypertension,
asthma, anemia, hyperglycemia, hypercholesterolemia, seasickness,
Raynaud's disease, alcohol abuse, smoking, obesity, poor oral hygiene,
herpes simplex infection, bacterial infection, common cold, pain,
nausea, ileus, infertility, cervical dilatation, labor, menopause,
prostatism, depression, schizophrenia, insomnia, anxiety, phobia,
14
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The degree of placebo effect often depends on the
nature of the intervention, i.e., some treatment modalities
are more efficacious than others. In general, injections are
more potent than oral medication, capsules work better than
tablets, brightly colored remedies are more efficacious than
muted colors, and two pills work better than one.18
III. Placebos in Clinical Medicine
For practicing physicians, there are clear advantages
and disadvantages to the clinical use of placebos. Each
practitioner must weigh the benefits and risks in any given
circumstance and decide whether placebo use is indicated.
This section will consider the pros and cons of placebo use
as well as its impact on health care.
A. Pros
Placebos are arguably an ideal treatment. Numerous
studies demonstrate the efficacy of the little "sugar pill."
These inert substances or simulated treatments
fundamentally lack organic side effects.19 Placebos are
considerably less dangerous than genuine drugs because
they confer no direct toxicity.20 There is no physical risk;
thus, the dominant consideration is efficacy.
In general, doctors are acutely aware of the
vicissitudes of medicine and the challenge of giving
meaningful, comprehensible and correct answers to
compulsive nail biting, mental handicap, marital discord, stress related
to dental treatment, orgasmic difficulties, fecal soiling, enuresis,
epilepsy, Parkinson's disease, Alzheimer's disease, attention-deficit-
hyperactivity disorder, carpal syndrome, and undiagnosed ailments).
18 DAN J. TENNENHOUSE, 3 ATTORNEY'S MEDICAL DESKBOOK §
38.2.40 (4th ed. 2006 & Supp. 2010).
1 Brody, supra note 10, at 18.
20 Paul Enck, Fabrizio Benedetti & Manfred Schedlowski, New Insights
into the Placebo and Nocebo Responses, 59 NEURON 195, 202 (2008).
15
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patients. There are diseases that are untreatable but patients
insist on some instrumentality. If nothing is offered,
patients depart feeling dissatisfied, neglected, and
shortchanged. If they feel worse at the conclusion of the
visit than at its inception, the encounter has been a disaster
and the doctor-patient relationship is in peril. The placebo
effect can confer a therapeutic advantage even when there
is no effective treatment. When the disease is incurable and
the situation is hopeless, the placebo offers a "treatment"
option. When their physical or psychological needs remain
unattended, there is a danger that patients will go doctor-
shopping and receive inappropriate or overly aggressive
medical care from a less skilled or more self-serving
healthcare provider. Perhaps the patient will resort to
dangerous Google self-treatment.
Patients often present with vague, non-specific
complaints that are not pathognomonic for any particular
illness. Underlying psychological or situational difficulties
are frequently the genesis of these symptoms. Rather than
resort to speculative polypharmacy, a placebo may be both
less toxic and more effective. If the problem disappears
with the placebo, it was most likely psychogenic. Side
effects and drug habituation are avoided.
A study of Swiss healthcare providers revealed the most
common indications or reasons for placebo use:
1. pain
2. insomnia
3. anxiety
4. risk of substance abuse
5. difficult or demanding patients
6. patient request
7. to invoke the placebo effect
8. to avoid conflict with patients
9. as a supplement to standard treatment
10. for non-specific symptoms
16
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11. to avoid informing patients that treatment
possibilities were exhausted. 2 1
B. Cons
When placebo use displaces comprehensive medical
evaluation and treatment, the placebo effect may mask
symptoms and delay the indicated treatment of the medical
22
condition. One of the most egregious examples of placebo
use in lieu of well-established treatment occurred in rural
23Alabama between the years 1932 and 1972. During the
period, African-American men were screened for "bad
blood" and then lured into a government sponsored
"treatment" program. In reality, the United States Public
Health Service screened these men for tertiary syphilis.
Rather than receiving penicillin, 399 infected men were
treated with placebos. They were neither informed about
their syphilitic infection nor given information regarding its
treatment or prevention. The purpose of the study,
inconceivable in this day and age, was to study the long-
term effects of an untreated disease.24 Catastrophes like this
remind us of other dark periods in human history when
people were abused or tortured based solely on their race or
religion. Unfortunately, the use of placebos is sometimes
viewed through this lens.
The antithesis of the placebo effect is the "nocebo
phenomenon."25 While placebos produce beneficial results,
like genuine therapeutic agents, they can have associated
toxic, or nocebo, effects. Beecher observed thirty-five
21 Fissler, supra note 6, at 5.
22 Paul Hibert, Barry Hoffmaster, Kathleen Glass & Peter Singer,
Bioethics For Clinicians: Truth Telling, 156 CAN. MED. Ass'N J. 225,
226 (1997).
23 Amy L. Fairchild & Ronald Bayer, Uses and Abuses of Tuskegee,
SCIENCE, May 7, 1999, at 919.
24 id.
25 Barsky, supra note 12, at 622.
17
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different toxic effects of placebos. The incidence of side
effects was: dry mouth, nine percent; nausea, ten percent;
sensation of heaviness, eighteen percent; headache, twenty-
five percent; difficulty concentrating, fifteen percent;
drowsiness, fifty percent; warm glow, eight percent;
relaxation, nine percent; fatigue, eighteen percent; and
sleep, ten percent.26 Professor Marshall B. Kapp noted
placebo-related side effects in five to ten percent of
27
patients. His list of observed nocebo effects was even
more comprehensive: nausea, thirst, headache, dizziness,
sleepiness, insomnia, fatigue, depression, numbness,
vomiting, tremor, fast heart beat, hives, diarrhea, blood
pressure changes, pallor, skin rashes, swelling, and
unsteady gait.2
Medical students were evaluated in a clinical trial
using placebos to assess nocebo effects on otherwise
normal subjects.29 Twelve subjects were each given red and
white gelatin capsules with lactose, green, and yellow
gelatin capsules with lactose, or a drink of water.3 o The
students taking the colored capsules reported the following
fourteen symptoms: flushing of face, euphoria, anxiety,
irritability, restlessness, inability to concentrate, thirst,
tremors, sedation, headache, bradycardia, dysphoria,
flatulence, and diuresis.31 Moreover, eight of twelve of the
red/white group and ten of twelve of the 3reen/yellow
group reported side effects from the placebos.
Placebo treatment can be costly. Many individuals
correlate effectiveness with cost. In other words, the cheap
26 Beecher, supra note 13, at 1603.
27 Kapp, supra note 8, at 375.
28 id.
29 C.W. Gowdey, J.T. Hamilton & R.B. Philp, A Controlled Clinical
Trial Using Placebos in Normal Subjects: A Teaching Exercise, 96
CAN. MED. Ass'N J. 1317, 1317 (1967).30 id.
31 Id. at 1318.
32 Id. at 1319-20.
18
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stuff is garbage. Spurious procedures still require
equipment and professional time. Taken to extremes, the
cost of a fictitious surgical procedure complete with an
operating room, personnel, and surgical packs would be
enormous. Even when the patient pays the price, the
efficacy of the placebo effect is still questionable in any
given circumstance.
There are emotional risks to the long-term use of
placebos. In general, the potency of the placebo effect
diminishes with time, inducing something akin to
tachyphylaxis. Psychological dependency may develop,
requiring increasingly large doses of placebo and
withdrawal sym toms when administration ceases.33
Fissler extensively analyzed the frequency of
placebo use in clinical medicine by reviewing twenty-two
studies conducted from 1973 to 2009. The percentage of
physicians who reported using placebos at least once was
highly variable. Between seventeen and eighty percent used
pure placebos; fifty-four to fifty-seven percent used impure
placebos; and forty-one to ninety-nine percent used pure
and/or impure placebos. Saline injections, sugar pills or
prepared placebo tablets were the most popular modalities.
Impure placebos included antibiotics for viral infections as
well as vitamins and analgesics for problematical
indications. The results indicated that a significant
proportion of physicians and nurses have used pure
placebos at some point in clinical situations, but the number
of frequent users was de minimis. Impure placebos,
especially superfluous antibiotics, were more likely to be
used with frequency.
Placebo use amonf Swiss primary care providers
has been closely studied.3 Seventy-six percent of the two
33 Oldrich Vinar, Dependence on a Placebo: A Case Report, 115 BRIT.
J. PSYCHIATRY 1189, 1190 (1969).
34 Fsser, supra note 14, at 2.
35 Fdssler, supra note 6, at 1.
19
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hundred doctors polled have used bland ointments and/or
bandages for contusions without any apparent skin
damages. Sugar pills and saline injections were only used
by ten percent. Almost two thirds of doctors have
prescribed therapies, such as vitamins or antibiotics,
without an approved indication or an expectation of
efficacy. Regarding diagnostic exams, the sophistication of
the test was inversely proportional to the frequency of its
use. Eighty-nine percent of physicians admitted to
performing unnecessary physical exams; sixty-nine percent
ordered non-essential technical exams with no inherent risk
(e.g., ultrasound, MRI); and thirty-one percent prescribed
non-essential technical exams with some inherent risk (e.g.,
CT scans).
Americans receive a considerable amount of
placebo-related care without being cognizant of it. One-
third of Americans turn to alternative medicine, including
massage, homeopathy, spiritual healing, and
36
megavitamins. Evidently, the total number of visits to
non-allopathic care providers each year exceeds the number
of visits to primary care physicians. While self-styled
healers and their patients are convinced of the efficacy of
megavitamins and herbal potions, these popular remedies
derive their benefit predominantly from the placebo
effect.37
There is considerable evidence to suggest that
homeopathy is placebo medicine. Dr. Wayne B. Jonas
analyzed four independent, comprehensive reviews to
evaluate whether homeopathic remedies and placebos were
equivalent in double-blind, randomized studies. 38Al
homeopathic remedies are highly diluted; a small quantity
36 Walter A. Brown, The Placebo Effect, SCIENTIFIC AMERICAN, Jan.
1998 at 90, 95.
37 Id.
3 Wayne B. Jonas, Ted J. Kaptchuk, & Klaus Linde, A Critical
Overview of Homeopathy, 138 ANNALS INTERNAL MED. 393, 395
(2003).
20
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of either a 1:10 or 1:100 solution is further diluted six to
twelve times. 39 For the higher dilution (1:100 x 12), the
probability of finding a single molecule of the "active"
ingredient in a one-liter volume is sixty percent. In other
words, if you drink a quart of the concoction, about one
half of the time you will ingest a single molecule of the
"active" ingredient. Because the doses are virtually non-
existent, most authorities assume that homeopathy is safe
and its elixirs will not interact with conventional drugs.40
This is invariably true since the compounds are not
pharmacologically active. Jonas' study concluded that there
is scant evidence that homeopathy is effective for any
specific clinical condition. In other words, the
homeopathic remedy itself functions as a placebo.
IV. Neuroscience
A neurologist injures her knee skiing and visits the
orthopedist. The orthopedist asks, "Where does it hurt?"
The neurologist smiles and says, "In my head, of course."
Neuroscience has taken a perspicacious look into
the effects of placebos on the brain, usually in the context
of pain relief. A considerable amount of information has
already been amassed. Tor Wager is widely recognized for
studying the nexus between placebos, the experience and
anticipation of pain, and functional magnetic resonance
imaging (fMRI) changes.42 His work was further confirmed
39 Id.
40 Id.
41 Id. at 397.
42 Tor Wager, James Rilling, Edward Smith, Alex Sokolik, Kenneth
Casey, Richard Davidson, Stephen Kosslyn, Robert Rose & Jonathan
Cohen, Placebo-Induced Changes in fMRI in the Anticipation and
Experience of Pain, SCIENCE, Feb. 20, 2004, at 1162.
21
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by Dr. Jon-Kar Zubieta using positron emission
tomography (PET scan).43
Wager found that placebo manipulations decrease
brain activity in regions known to be pain-sensitive, and
that this decrease correlates with a reduction in subjective
pain." Two studies involving induced pain with electric
shock or thermal stimulus demonstrated these findings.
Previously identified placebo responders were randomized
into two groups.45 The placebo group was told that they
were getting a pharmacologically active analgesic; the
control group was told that their pill was ineffective against
pain. Only the placebo group evinced a statistically
significant reduction in perceived pain and a divergence in
brain activity. First, placebo analgesia was correlated with
decreased brain activity in pain-sensitive brain regions,
including the thalamus, insula, and anterior cingulate
cortex, and with increased activity in the prefrontal cortex.
Second, there was an increase in prefrontal activity even
before the pain stimulus was administered. The anticipation
of a painful stimulus coupled with expectations of pain
relief was associated with heightened activity in the
dorsolateral prefrontal cortex (associated with cognitive
control) and the orbitofrontal cortex (associated with
allocation of control).46
Placebo analgesia is mediated by both opioid and
non-opioid pathways. Analgesia can be partly blocked by
the drug, Naloxone, a competitive antagonist of the g-
opioid receptor frequently used to treat opioid overdose.
The blockade confirms the importance of endogenous
opioids in the placebo response. Moreover, the effect of
43 Jon-Kar Zubieta, Joshua A. Bueller, Lisa R. Jackson, David J. Scott,
Yanjun Xu, Robert A. Koeppe, Thomas E. Nichols & Christian S.
Stohler, Placebo Effects Mediated by Endogenous Opioid Activity ony -
Opioid Receptors, 25 J. NEUROSCIENCE 7754, 7755, 7760 (2005).
4 Wager et al., supra note 42, at 1165.
45 Id. at 1162-66.
46 Id. at 1163-64.
22
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Naloxone was greater when the subjects had strong
expectations regarding the pain relieving effects of the
placebo. This was consistent with the notion that
expectations of analgesia were associated with increased
local release of endogenous p-opioids. On the other hand,
even when subjects had no expectation cues, the placebo
still manifested pain relieving effects not blocked by
Naloxone, supporting the existence of the non-opioid
pathway.47
Neuropharmacologists have further differentiated
placebo analgesia pathways based on whether the analgesia
was activated by the expectation of relief or by prior
conditioning. Experimental subjects underwent
pretreatment conditioning with morphine or Ketorolac, an
anti-inflammatory medication with analgesic effects, prior
to the application of painful tourniquet pressure. Groups
were then given morphine, Ketorolac, Naloxone, or a
placebo to attenuate the pain. Two main findings emerged
from the study. Those subjects who believed they had
received an analgesic and expected relief of pain noted
significantly less pain. Therefore, endogenous opioid
systems are triggered by cognitive factors, specifically
verbal expectation. In contrast, placebo responses induced
by conditioning were not exclusively mediated by
endogenous opioids. While placebo analgesia after
morphine conditioning did utilize the opioid pathway,
Ketorolac conditioning did not. Ketorolac used the cyclo-
oxygenase pathway characteristic of all non-steroidal anti-
inflammatory drugs at the level of peripheral and central
sites in the spinal cord.48
47 Fabrizio Benedetti, Helen S. Mayberg, Tor D. Wager, Christian S.
Stohler, and Jon-Kar Zubieta, Neurobiological Mechanisms of the
Placebo Effect, 25 J. NEUROSCIENCE 10390, 10390 (2005).
48 Martina Amanzio & Fabrizio Benedetti, Neuropharmacological
Dissection of Placebo Analgesia: Expectation-Activated Opioid
Systems versus Conditioning - Activated Specific Subsystems, 19 J.
NEUROSCIENCE 484, 490 (1999).
23
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In 2011, Wager reanalyzed his original studies to
assess individual variations in the robustness of placebo
effect. fMRI activity was observed at two points - during
the anticipation of pain and while experiencing pain. The
fMRI showed that increased anticipatory activity in the
frontoparietal network and decreased activity in the
posterior insular/temporal network were predictive of the
magnitude of placebo analgesia. The most predictive
regions were those associated with emotional appraisal
rather than cognitive control or pain processing. Wager
concluded that engagement of emotional appraisal circuits
is the driving force behind the perceived individual
variation in placebo analgesia, rather than early suppression
49of nociceptive processing.
While most placebo-related neuroscientific inquiries
have considered analgesia, there is growing interest in the
effect of placebo on motor control in Parkinson's disease.
Patients who exhibited improved motor control after
placebo administration demonstrated activation of
endogenous dopamine release on Positron Emission
51Tomography (PET) scans.
PET scans were obtained on a group of clinically
depressed men who participated in an inpatient,
randomized, placebo-controlled study of the antidepressant,
Fluoxetine (Prozac). Scans were performed at three
separate intervals: before treatment (baseline), at one week,
and at six weeks. After six weeks, subjects who
experienced a clinical response were assessed and change
patterns for each individual were determined; then scans
from the treatment and placebo groups were compared.
Anatomically overlapping changes were evident at six
49 Tor D. Wager, Lauren Y. Atlas, Lauren A. Leotti & James K.
Rilling, Predicting Individual Differences in Placebo Analgesia:
Contributions of Brain Activity during Anticipation and Pain
Experience, 31 J. NEUROSCIENCE 439, 439 (2011).
50 Benedetti, supra note 47, at 10392.
51 Id.
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weeks between the Fluoxetine and placebo groups. Both
groups manifested corresponding increases in glucose
metabolism in the prefrontal, parietal, and posterior
cingulate regions, as well as a decrease in subgenual
cingulate. The only variation was that the regional changes
in the Fluoxetine-treated group were of greater magnitude
than the placebo group. 52
In summary, placebo analgesia is mediated by both
opioid and non-opioid pathways, just like
pharmacologically active substances. The placebo effect in
Parkinson's disease and depression correlates with altered
metabolic activity in neuroanatomical areas known to be
impaired in these conditions.
V. Ethics
The use of placebos poses four ethical questions
regarding deception, autonomy, malfeasance, and justice.
Ethicists find deception the most problematic.
Conceptually, many individuals maintain that deception of
any kind is morally objectionable. Truth in disclosure is a
fundamental aspect of the autonomy and dignity of human
beings. Deontology considers manipulation and deception
to be a manifestation of disrespect between people.
Deception is condemned because it "violates an a priori
moral rule-a priori because the rule appeals to the very
nature of our beings (that is, persons deserving respect)
rather than to the good or bad consequences of our
actions." 53
Most people believe that doctors should be
prescribing genuine medication. The prescription of
52 Helen S. Mayberg ET AL., Regional Metabolic Effects of Fluoxetine
in Major Depression: Serial Changes and Relationship to Clinical
Response, 48 BIOLOGY PSYCHIATRY 830, 836 (2000).
53 Howard Brody, The Lie That Heals: The Ethics of Giving Placebos,
97 ANNALS INTERNAL MED. 112, 113 (1982).
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placebos can be deceptive in three ways. Doctors may: (1)
lie about what the medication is; (2) make vague statements
about the medication; and (3) say nothing about the
medication. 54 The utilitarian responds, "So what? Who
cares as long as it works?" The utilitarian summates all the
favorable consequences attributable to placebos, and argues
(or assumes) that these outweigh the evils of deception. To
prove value, it is necessary only to show that using
placebos will increase the sum total of happiness in the
world.ss
Armageddon occurs when the patient discovers that
a placebo has been used. Physicians who endeavor to
deceive patients by representing placebos as
pharmacologically active medications risk undermining
their patients' trust.56 Once trust and confidence are
undermined, any hope for a productive physician-patient
relationship is decimated. Every treatment or intervention is
suspect. The motives and candor of the doctor will always
be uncertain. The consequences go well beyond individual
relationships. Patients, in general, may relinquish trust and
confidence in the entire medical profession. The efficacy of
bona fide prescription pharmaceuticals will be suspect.
Other options, such as medication with greater toxicity or
frank quackery, may be selected. In addition to rejecting
proper care, patients may opt for uninformed or
misinformed self-care.57 A computer trip to "Dr. Google"
could supplant a visit to the old style, bricks and mortar
medical office when illness strikes. Deception is a two-way
street; the doctor deceives the patient, and the patient
deceives the doctor. Future care would be based on
inadequate patient histories and failure to disclose self-
54 Kapp, supra note 8, at 376.
ss Brody, supra note 53, at 114.
56 Irwin Kleinman, Peter Brown, Larry Librach, Placebo Pain
Medication: Ethical and Practical Considerations, 3 ARCH FAMILY
MED. 453, 453 (1994).
5 See Kapp, supra note 8, at 377-78.
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treatment. The public may perceive doctors as charlatans,
and charlatans are not likely to promote healing with caring
explanations or the laying on of hands. To paraphrase
Simon and Garfunkel, "[Deception], like a cancer,
grows."5 By their very nature, deceptive practices fester,
and, as a result, defeat the conventional restraints of
obligation. Other parties in the healthcare system, such as
the nurse, pharmacist and medical assistant, become co-
conspirators.
Placebos are not simply inconsequential "white
lies." The monetary cost of prescription placebos is
considerable. In order to be "potent," placebos cannot be
free of charge. If the fee for the placebo prescription is
considerable, someone will be making an unjustifiable
profit. If it is too low, the patient may be suspicious of a
contrivance.59 Large expenditures of both time and money
may be required for placebo therapy. There is evidence that
increasing the cost of a prescription, thus making the
remedy appear more valuable and exotic, enhances the
placebo effect. This can result in financial loss to private
and public third-party insurers who pay the pharmacy fees.
The Council on Ethical and Judicial Affairs of the
American Medical Association concluded that, "the
deceptive use of placebos is not ethically acceptable
because it may harm patients to a greater degree than it
helps them."60 Using placebos in a duplicitous fashion is
disfavored because it fundamentally conflicts with a
58 See generally SIMON & GARFUNKEL, The Sound of Silence, on
WEDNESDAY MORNING, 3 A.M. (Columbia Records 1964).
59 See Brody, supra note 53, at 114.
6 Robert M. Sade, Placebo Use in Clinical Practice, CEJA Report 2-1-
06, 2006 AMA HOUSE OF DELEGATEs, available at http://
www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ve
d=OCBOQFjAA&url=http%3A%2F%2Fwww.ama-
assn.org%2Fresources%2Fdoc%2Fethics%2Fcejarecs_- 2i06.pdf&ei=R
7jVTpyoK4iXgweZkNGAQ&usg=AFQjCNHPITUFFnONow6ViQs
Y_5qCpJnsOA&sig2=_XNilpMgbUcHE-BAgamaiA.
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doctor's professional obligation to promote patient welfare
and respect patient autonomy. The Council has elucidated
the three most objectionable circumstances where placebos
are utilized: (1) to serve the convenience of the physician
rather than to promote patient welfare; (2) to mollify the
demanding and difficult patient; and (3) to assuage a
patient with a complex problem that frustrates the
physician.61
Since the emergence of the movement away from
paternalistic medicine, patient autonomy has become of
paramount importance in the physician-patient relationship.
Placebos are the antithesis of patient autonomy. Autonomy
and dignity are violated when the patient is deprived of an
opportunity to play a meaningful role in her care. It is the
patient's prerogative to make significant life decisions, to
participate fully, and to cooperate effectively. The
physician has an ethical and fiduciary duty to disclose
material facts and the patient has a duty to share
responsibility for the treatment. 62
Malfeasance is a concern when physical harm is
directly or indirectly inflicted. Placebo-induced side effects
are considered a direct harm. Harm is also caused when a
doctor prescribes a placebo to ameliorate subjective
symptoms either before or in lieu of a comprehensive
medical or psychiatric examination, when that examination
would have revealed a significant, treatable illness.
Placebos can induce dependency on a number of levels. By
its very nature, the dependency is psychological and,
arguably, a falsity. This dependency is unhealthy and may
result in actual addiction. Individuals may evolve into
"professional patients" - every symptom must be treated;
unexplained maladies come and go with the assistance of a
doctor who uses her sample closet and prescription pad
liberally. Constant treatment with magical liquids or
28
61 Id.
62 See Kapp, supra note 8, at 378-79.
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capsules can supplant the preventative paradigm. No longer
will people feel the need to maintain a healthy lifestyle and
use common sense.63
It is axiomatic that similar individuals with similar
medical problems should be treated equally, or at least
similarly. This basic principle of justice is easily violated
when placebo therapy leads to disparate treatment. The risk
is especially acute in the context of overly demanding and
querulous patients who are given placebos based on the
likelihood that they are overstating their level of pain.
Physicians ma feel the need to prove that the patient is not
actually sick.
There are, however, a number of arguments in favor
of the ethical acceptance and use of placebo. First,
contemptible deception can be eliminated by telling the
patient the nature of the treatment. Once prevarication is
eliminated, the ethical problem is defused. While the
outcome for an informed patient may not be comparable to
one who is deceived, undisguised placebo treatment is still
associated with a modest rate of success. The earliest
empirical rejection of the traditional deception-based
heuristic of the placebo response was a non-blind placebo
trial of fourteen psychiatric outpatients with somatic
symptoms. Each was treated for one week with sugar pills.
Subjects were candidly informed that they were taking
sugar pills with the caveat that many patients experienced
relief with such medication despite the absence of active
ingredients. Thirteen patients (ninety-three percent)
experienced some degree of subjective or objective
symptom reduction.
63 See id. at 380.
6 James S. Goodwin, Jean M. Goodwin & Albert V. Vogel, Knowledge
and Use of Placebos by House Officers and Nurses, 91 ANNALS
INTERNAL MED. 106, 109 (1979).
65 Lee C. Park & Uno Covi, An Exploration of Neurotic Patients'
Responses to Placebo When Its Inert Content is Disclosed, 12 ARCH.
GEN. PSYCHIATRY 336, 338 (1965).
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Certain levels of deception may be acceptable.
Placebo treatment can be used without the need for an
outright verbal lie. It may be more palatable to deceive a
patient in a nonverbal fashion using gestures or visual
clues. The placebo effect can be enhanced by the
environment in which the prescription is written. "The
setting in a doctor's office or hospital room, the impressive
terminology, the mystique of the all-powerful physician
prescribing a cure - all of these tend to give the patient faith
in the remedy." 66
If a deception is benevolent, is it any less
objectionable? Physicians use placebos for benevolent
purposes, i.e., to improve the well-being of their patients. A
benevolent lie used to evoke a placebo effect may be
sufficiently virtuous for some.6 7  In addition, patients
sometimes prefer to be lied to. It is not improper to oblige
them. Patients commonly return decision-making power to
physicians by not asking for information or
recommendations, "but instead pledge - by word or
conduct - to follow whatever course of action the physician
feels is appropriate."68 A patient's implicit or explicit
consent to be deceived renders a lie ethical. There are
situations in which lying to a patient is considered humane
if it fulfills the patient's wishes. For some, maintaining
hope or even the illusion of hope even in the face of near
hopelessness improves the quality and duration of life over
the short term by eliciting a placebo effect.6 9
Swiss health providers have tried to justify placebo
use by differentiating between pure and impure placebos.
They contend that use of pure (inert) placebos is ethically
unacceptable because it dupes the patient and promotes an
66 See Bok, supra note 2, at 19.
67 Kathleen M. Boozang, The Therapeutic Placebo: The Case for
Patient Deception, 54 FLA. L. REV. 687, 725 (2002).
68 See Kapp, supra note 8, at 385.
69 See Boozang, supra note 67, at 753.
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outdated, unduly paternalistic relationship. These
practitioners justify the use of impure (pharmacologically
active) placebos with the casuistic argument that active
drugs, even those not indicated for the disease in question,
could conceivably confer a positive effect on the health of
the patient.70
VI. Law
Legal issues regarding placebo treatment have not
materialized in court cases, legislation, or federal and state
regulation because patients have not been informed that
they are taking placebos. The law does not specifically and
overtly regulate the use of placebos except in the context of
the patient's right to pain management. 7  When the United
States Supreme Court considered an individual's right to
choose physician-assisted suicide, it affirmed an
individual's right to refuse pain management and
appropriate palliative care. 72
Timothy Quill, M.D. challenged the illegality of
prescribing lethal medication to terminally ill, mentally
competent patients in Vacco v. Quill.73 The United States
Supreme Court held that physician-assisted suicide was
impermissible based on the theory of causation and intent.
Justice O'Connor, concurring in another "right-to-die"
case, affirmed that a terminal patient in great pain "has no
legal barriers to obtaining medication . . . to alleviate that
suffering, even to the point of causing unconsciousness and
70 See Fissler, supra note 6, at 7.
7' Karen J. Nichols ET AL., AOA's Position Against Use ofPlacebos for
Pain Management in End-of-Life Care, 105 J. AM. OSTEOPATHIC
ASS'N S2, S3-4 (2005) (discussing legislation regarding a patient's
right to pain management).
72 Vacco v. Quill, 521 U.S. 793, 808 (1997).
73 Id. at 793.
31
24
Tennessee Journal of Law and Policy, Vol. 8, Iss. 1 [2012], Art. 3
http://trace.tennessee.edu/tjlp/vol8/iss1/3
8.1 Tennessee Journal of Law and Policy 32
hastening death." 74 Placebo substitution for active analgesic
medication, however, without the express informed consent
of the individual violates the precepts of the American Bar
Association.7 5
A cause of action for placebo-related damages can
be brought under the theories of fraud, false advertising,
lack of informed consent and medical malpractice.
A. Fraud
The elements of fraud giving rise to the "tort action
for deceit are: (a) misrepresentation (false representation,
concealment, or nondisclosure); (b) knowledge of falsity
(or 'scienter'); (c) intent to defraud, i.e., to induce reliance;
(d) justifiable reliance; and (e) resulting damage." 76 It is
apparent that each element of the cause of action is
potentially present in a case where placebos are
mendaciously used, regardless of whether an outright lie, a
vague and non-committal statement, or silence concerning
the nature of the treatment is involved. Intent to harm the
plaintiff is not requisite.7 7
In Jurcich v. General Motors Corp., an employee
brought an action in fraud and deceit against the
corporation and its nurse employee for repeatedly treating
him for pain with sugar pills, without his knowledge, after a
job-related injury.7 8 The issue for the court was whether
this case should be brought under the rubric of fraud or
74 Washington v. Glucksberg, 521 U.S. 702, 737 (1996) (O'Connor, J.,
concurring) (Justice O'Connor's concurring opinion also applies to
Vacco, 521 U.S. at 809).
75 Nichols, supra 71, at S4.
76 Southern Union Co. v. Southwest Gas Corp., 180 F. Supp. 2d 1021,
1030 (D. Ariz. 2001) (internal quotations and citations omitted).
77 See Kapp, supra note 8, at 388.
78 Jurcich v. General Motors Corp., 539 S.W.2d 595, 595 (Mo. Ct. App.
1976).
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medical malpractice. 79  The court held that medical
malpractice was the appropriate theory, not fraud and
deceit. Further, the court observed that the prescription of
placebos "is, in appropriate cases, a recognized form of
medical treatment." The court concluded that the plaintiff
was not injured by the placebo by holding that "[t]here is
not a scintilla of evidence in this record that by the
dispensing of placebos to him his back injuries were
worsened nor that any new injuries resulted. He simply
obtained no relief from his pain."81 The court viewed the
use of a placebo as proper under certain circumstances, and
the issue in the case was the medical standard of care. 82
B. Fraudulent Advertising
Courts have strongly disfavored the promotion and
advertising of over-the-counter placebos. The Federal
Trade Commission filed an action against the promoter of a
worthless hair loss product in FTC v. Pantron I Corp..83
The defendant-promoter asserted that there was scientific
evidence to support his claim of efficacq, but the court
established that any benefit was placebic. A seller may
not claim that a product is effectual when its effectiveness
is predicated solely on the placebo effect. That
representation "constitutes a 'false advertisement' even
though some consumers may experience positive results."85
The court in FTC v. QT, Inc. arrived at a similar
conclusion.86 The defendants used infomercials and print
advertising to market the Q-Ray Ionized Bracelet@ as a
'
9 Id. at 600.
80 Id.
81Id. at 601.
82 Boozang, supra note 67, at 740.
83 FTC v. Pantron I Corp., 33 F.3d 1088, 1088 (9th Cir. 1994).
4 See id. at 1097.Id. at 1100.
FTC v. QT, Inc., 448 F. Supp. 2d 908, 908 (N.D. Ill. 2006).
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device that provided significant, immediate, and complete
pain relief for conditions such as migraines and back pain
by emitting an unspecified ionizing force. The court found
no scientific evidence to substantiate the claims and held
that the bracelet was advertised in a dishonest and
materially misleading manner since any benefit from the
product was based solely on the placebo effect. The court
quoted United States v. An Article.. .ACU-DOT, "[a] kiss
from mother on the affected area would serve just as well
to relieve pain, if mother's kisses were marketed as
effectively...." 88
C. Informed Consent
Under the professional standard of informed
consent, a physician is required to make disclosures that a
reasonable physician would make under the circumstances.
The patient-oriented standard, on the other hand, "requires
physicians to provide patients with that information which
the 'reasonably prudent person would find material to
making a decision."'89 To establish a prima facie case
against a physician for failure to obtain informed consent,
the plaintiff must prove that:
1. the physician had a duty to disclose sufficient
information about a proposed treatment to
obtain the patient's informed consent;
2. the physician breached that duty;
3. the physician's failure to disclose adequate
information was the proximate cause of the
patient's decision to consent to a treatment to
which the patient would have withheld consent
if he or she had been adequately informed; and
87 See id. at 965.
88 Id. at 964 (citing United States v. An Article... ACU-DOT, 483 F.
Supp. 1311, 1315 (N.D. Ohio 1980)).
89 Boozang, supra note 67, at 739.
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4. a potential adverse consequence of the treatment
materialized, resulting in a detriment to the
patient.90
Hospital organizations promote the concept of
informed consent to their patients through brochures
distributed at the time of admission. The American
Hospital Association's brochure entitled, "The Patient Care
Partnership," urges patients to be actively involved in their
care:
INVOLVEMENT IN YOUR CARE
You and your doctor often make
decisions about your care before you go to
the hospital. Other times, especially in
emergencies, those decisions are made
during your hospital stay.
When decision-making takes place, it
should include:
* Discussing your medical condition and
information about medically appropriate
treatment choices.
To make informed decisions with your
doctor, you need to understand:
* The benefits and risks of each treatment.
* Whether your treatment is experimental
or part of a research study.
* What you can reasonably expect from
your treatment and any long-term effects
it might have on your quality of life.
* What you and your family will need to do
after you leave the hospital.
9 Bennett v. Surgidev Corp., 710 A.2d 1023, 1026 (N.J. Super. Ct.
App. Div. 1998) (citing Largey v. Rothman, 540 A.2d 504 (N.J. 1988);
Caputa v. Antiles, 686 A.2d 356 (N.J. Super. Ct. App. Div. 1996)).
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* The financial consequences of using
uncovered services or out-of-network
providers.91
The use of placebos creates a number of problems
with informed consent. In general, informed consent for
placebo use is not sought for two reasons: (1) the
usefulness of a placebo is abrogated when the patient
knows what it is; and (2) placebos have been considered
sufficiently harmless and beneficial to render disclosure
unnecessary.92 Some legal professionals surmise that
informed consent does not apply to the use of placebos. An
intervention must be potentially hazardous for issues of
informed consent to apply. Since placebos are prescribed in
clinical practice solely for symptomatic relief and not for
disease treatment, it has been argued that no ongoing harm
will result from substituting a placebo in place of a
prescription drug.93
Several other reasons circumventing full disclosure
have been articulated. First, one may construe a patient's
initial consent to treatment as ongoing consent to all
specific treatments that a physician employs, including the
use of a pure placebo. 94 Second, under existing consent
law, a patient does not need to be informed when a
physician chooses Treatment A over Treatment B, because
of the added placebo effect. 95 Third, when considering the
explication of potential treatment side effects, it is the
prerogative of the patient to decide whether he/she would
like to hear about them. Both legal and ethical ideations of
9' The Patient Care Partnership, BROCHURE (AMER. HosP. Assoc.
2003).92 Bok, supra note 2, at 19.
9 DAN J. TENNENHOUSE, 3 ArrORNEYS MEDICAL DESKBOOK § 38:2.50
(4th ed. 2006 & Supp. 2010).
94 Anup Malani, Regulation with Placebo Effects, 58 DUKE L.J. 411,
449 (2008).
9 See id. at 450-51.
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informed consent should provide for patients who truly
want to be deceived, or for whom the truth would be
therapeutically counterproductive.96 The physician may
also take into account whether the side effects are material
and whether current medical custom demands their
disclosure. 97
When enough physicians use placebos for
therapeutic purposes without disclosure, the lack of
disclosure evolves into the professional standard of care
and reframes notions of informed consent. 98 In other words,
the absence of disclosure will be consistent with the
"exercise [of] that degree of care, skill and learning
expected of a reasonable, prudent health care provider in
the profession or class to which he belongs within the state
acting in the same or similar circumstances." 99 Neither will
physicians encounter legal hurdles under a patient-oriented
standard. If, as previously argued, the reasonable patient
would opt to experience the benefits of placebo therapy
without having the truth revealed to her, then the legal
standard of disclosure, as determined by the reasonable
patient, would abide the deception.
D. Medical Malpractice
In Arizona, there are two elements of proof
necessary to show that an injury resulted from the failure of
a health care provider to follow the accepted standard of
care:
1. The health care provider failed to exercise that
degree of care, skill and learning expected of a
reasonable, prudent health care provider in the
96 Boozang, supra note 67, at 737.
9 Malani, supra note 94, at 452.
98 Boozang, supra note 67, at 739.
9 ARIZ. REv. STAT. § 12-563 (LEXIS through 2011 legislation).
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profession or class to which he belongs within the
state acting in the same or similar circumstances.
2. Such failure was a proximate cause of the
injury. 00
Plaintiffs must present facts from which negligence and a
causal relation between the injury and the defendant's acts
may be reasonably inferred. 01 The court "must find for the
defendant unless [it] finds a probability that defendant's
negligence was a cause of plaintiffs injury."102
With regard to the use of placebos, the basic rules
of medical malpractice hold. The issue in malpractice cases
is whether a doctor's treatment of a patient was negligent.
The answer hinges on whether the treatment works, not on
how it works.10 "The test for negligence is the same in all
cases: does the treatment conform to medical custom, or,
would a reasonable physician administer this treatment?"l04
There are three major considerations when a malpractice
action is based on the use of a placebo: (1) when a patient
suffers a negative placebo reaction reasonably foreseeable
to a competent doctor; (2) when appropriate treatment is
improperly impeded by the use of a placebo; and (3) when
the doctor's treatment of the patient with a placebo deters
the patient from obtaining effective treatment from another
practitioner.'os
E. Defenses
There are four main defenses to a placebo-related
claim. First, the patient suffered no harm; it is necessary to
' See id.
1o1 Harvey v. Kellin, 566 P.2d 297, 302 (Ariz. 1977).
102 Thompson v. Sun City Community Hosp., Inc., 688 P.2d 605, 616
(Ariz. 1984).
103 Melani, supra note 94, at 455.
104Id.
105 See Kapp, supra note 8, at 395.
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prove injury caused by the placebo treatment itself.'06
Second, use of the placebo was not negligent; similarly
trained professionals would also have prescribed a placebo
under comparable circumstances, consistent with the
accepted standard of care.107 Third, treatment without
informed consent and disclosure is conditionally
permissible where there is a reasonable likelihood that
exposing the nature of the treatment will cause
psychological harm, hinder or complicate treatment, or
impair the patient's ability to assent to treatment.' Thus,
therapeutic privilege is a well-recognized exception to the
objective standard of disclosure, and excuses the
withholding of information where disclosure would be
unhealthy to the patient. The privilege is applicable only if
disclosure of the information would complicate or hinder
treatment, cause such emotional distress as to preclude a
rational decision, or cause psychological harm to the
patient."' 09
Fourth, while the patient has the right to know the
risks, benefits and alternatives of a medical intervention,
the patient similarly possesses "the prerogative to waive or
relinquish that right.""l0 According to the California
Supreme Court, "a medical doctor need not make
disclosure of risks when the patient requests that he not be
so informed... Such a disclosure need not be made if the
procedure is simple and the danger remote and commonly
appreciated to be remote."' 1
'0 See id. at 396.
' See id.
108 See id. at 397.
109 Canterbury v. Spence, 464 F.2d 772, 789 (D.C. Cir. 1972).
110 Kapp, supra note 8, at 399.
"' Cobbs v. Grant, 502 P.2d 1, 12 (Cal. 1972).
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VII. Recommendations
Each Monday, hundreds of thousands of doctors
return to work, evaluate patients, and select the most
effective treatment available under the circumstances. At
some point in her professional practice, a doctor has to
decide if and when a placebo might be appropriate. This
section will look at possible uses of placebos that may be
sanctioned by ethicists and legalists.
A. When Placebos May Not Be Used
There is a consensus against placebo therapy being
used as a tool of convenience for the practitioner. Placebo
therapy is not a tool of mollification for demanding patients
or those with frustrating and complex medical problems.11 2
It is not a profit center for dispensing physicians. It is not a
substitute for practicing medicine.
Bona fide treatments that are safe and effective for
the patient's condition are preferable to placebos. The use
of a placebo is unwarranted before a careful history and
physical exam is performed, a differential diagnosis is
established, the appropriate laboratory and radiological
investigation have been carried out, and necessary
consultations have been obtained. No impure placebo
should ever be used.
When the placebo treatment has been selected, it
should only be used for a specific purpose. Therapeutic
results must be carefully monitored and the duration of
treatment must be strictly defined. Placebos should be
dispensed or administered by a doctor's orders. There is no
place for over-the-counter placebos.11 3 Healthcare facilities
112 Kapp, supra note 8, at 381-82.
"13 Christie Aschwanden, Experts Question Placebo Pill for Children,
N.Y. TIMES, May 27, 2008, at F5 (Jennifer Buettner successfully
treated her hypochondriacal niece with a placebo in order to avoid the
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need written policies governing their use." 4 Outright lies
are unacceptable and patient questions must be answered
candidly." Placebos should not be dispensed to patients
who specifically ask not to receive them. 16
B. When Placebos May Be Used
Placebo treatment has been suggested in the
following situations:
(1) Patient shows no benefit from standard therapy;
(2) Patient is dependent on morphine or other
addictive narcotics or sedatives and needs to be
gradually weaned off of them;
(3) Patient has a mild condition and the risk-to-
benefit ratio militates against the use of potent
medications with significant risks of toxicity or
addiction;
(4) Patient is psychologically unable to deal
rationally with candid evaluation of their medical
condition;
(5) Parents who insist that treatment must be
prescribed for their children;
(6) Patients who demand treatment preceding a
thorough diagnostic evaluation;
potential side effects of unnecessary antibiotics or other medications.
She started Efficacy Brands, a company that markets a supplement,
Obecalp (placebo spelled backwards). It is a cherry-flavored sugar pill
designed to simulate the texture and flavor of medication and is
marketed as a dietary supplement with no active drug. The placebo was
supposed to be available on the website, http://www.
inventedbyamother.com/, at fifty tablets for $5.95 or in liquid form at
retail locations across the country. However, as of January 8, 2012, it is
not. The only available placebo is "PlacebO Pilules," sold by Universal
Placebos, $20 Australia for 700 small pills, available at http://
www.placebo.com.au).
114 Kapp, supra note 8, at 402.
"' See id.
116 See id.; Bok, supra note 2, at 22.
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(7) Patients who are terminally ill and require
reduction in analgesic medication due to severe side
effects; and
(8) Patients who may benefit from an adjunct to
standard therapy." 7
For example, the following are circumstances where a
placebo may prove exceedingly helpful:
* An overly anxious patient who recently sustained a
myocardial infarction and is at risk for a fatal
arrhythmia, but refuses tranquilizers to reduce her
stress level.'1 8
* A patient who presents with significant symptoms
from a treatable condition but refuses medication
because of potential side effects. An example is a
post-menopausal woman with irritability and
depression who refuses estrogen replacement.119
* A child with attention deficit hyperactivity disorder
who requires progressively more medication with
attendant side effects. The placebo is given to
enhance the effect of smaller doses of the active
drug.120
117 Kapp, supra note 8, at 383-84.
118 See id. at 402.
"9 See id. at 403.
120 Adrian S. Sandler, Corrine E. Glesne, James W. Bodfish,
Conditioned Placebo Dose Reduction: A New Treatment in Attention-
Deficit Hyperactivity Disorder?, 31 J. DEV. & BEHAV. PEDIATRICS 369,
372-73 (2010) (Children with attention deficit hyperactivity disorder
who took half their usual dosage of active medication in conjunction
with an undisclosed placebo had the same therapeutic effect as their
prior full dosage. Patients who took half their dose without placebo
showed a reduced therapeutic effect).
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VIII. Conclusion
Placebos will always have a place in clinical
medicine. They are useful for individuals who manifest a
significant placebo effect, especially when their symptoms
do not justify intervention with potent medications. But,
there will never be a substitute for a competent and
comprehensive diagnostic evaluation. The neuroscience of
placebos shows activation and inhibition of the same
anatomical pathways and receptors that are targeted by
standard pharmaceuticals.
Most of the ethical objections focus on the issue of
deception and its capacity to destroy both the doctor-patient
relationship and the standing of physicians in society.
Placebo law is not well developed, but placebo use does
raise issues of fraud, lack of informed consent, and medical
malpractice. Their use may be defended by their relative
safety and efficacy. There are solutions to deception and
informed consent problems, including the use of limited or
full disclosure. In certain circumstances, where treatment is
not warranted or not possible, the placebo effect can be
utilized to make certain patients feel better. Any
intervention in medicine is always a question of whether
the benefits outweigh the risks. There are numerous cases
in which placebos confer enormous benefits with minimal
risk. They should be used sparingly and circumspectly, but
they should be used.
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